-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $273

Benzinga·06/23/2026 14:00:47
Listen to the news
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $265 to $273.